2020
Commentary on “Window to His World: Using a Patient’s YouTube Channel to Help Diagnose Chronic Mania”
Garakani A. Commentary on “Window to His World: Using a Patient’s YouTube Channel to Help Diagnose Chronic Mania”. Journal Of Psychiatric Practice 2020, 26: 324-328. PMID: 32692131, DOI: 10.1097/pra.0000000000000480.Commentaries, Editorials and LettersBipolar DisorderDiagnostic and Statistical Manual of Mental DisordersHumansMaleManiaRetrospective StudiesSocial Media
2008
Effect of medication and psychotherapy on heart rate variability in panic disorder
Garakani A, Martinez JM, Aaronson CJ, Voustianiouk A, Kaufmann H, Gorman JM. Effect of medication and psychotherapy on heart rate variability in panic disorder. Depression And Anxiety 2008, 26: 251-258. PMID: 18839407, DOI: 10.1002/da.20533.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleElectrocardiographyFemaleHeart RateHumansLife Change EventsMaleMiddle AgedPanic DisorderPsychotherapySelective Serotonin Reuptake InhibitorsSertralineYoung AdultConceptsHeart rate variabilityHeart rateRate variabilityLower heart rate variabilitySignificant clinical improvementWeeks of treatmentWeeks of CBTEffects of medicationPanic disorder patientsEffect of treatmentClinical improvementCardiac riskPD patientsCardiovascular diseaseTreatment respondersClinical measuresElevated riskDisorder patientsTreatment phasePatientsSymptom reductionPanic disorderHyperventilation challengeStatistical ManualSignificant decreaseShort-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study
Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. Clinical Therapeutics 2008, 30: 1658-1666. PMID: 18840371, DOI: 10.1016/j.clinthera.2008.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Anxiety AgentsAnxiety DisordersDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleFemaleHumansMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesSerotonin 5-HT1 Receptor AgonistsSerotonin Receptor AgonistsSingle-Blind MethodSulfonamidesSurveys and QuestionnairesTreatment OutcomeConceptsGeneralized anxiety disorderShort-term tolerabilityAdverse eventsPRX-00023Hamilton Anxiety Rating Scale scoresVital signsResponse criteriaAnxiety disordersTotal scoreOpen-label studySerotonin 1A agonistSingle-blind placeboAnxiety Rating Scale scoresSerious adverse eventsStudy end pointInfluenza-like symptomsOpen-label treatmentPrimary outcome measureDiagnosis of GADRating Scale scoresEnd point changeSample of patientsSerotonin 1A receptorPremature ventricular contractionsSelective partial agonist